BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth

Published on 10/01/2026 at 00:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioMarin Pharmaceutical stock faces a VOXZOGO setback after the company ended a Noonan syndrome program on September 15, 2026. Q2 revenue rose 20.00 percent.

BMRN, US09061G1013, Illustration mit AI erstellt.

BioMarin Pharmaceutical (ISIN US09061G1013) faces a strategic setback after ending a VOXZOGO development program for children with Noonan syndrome on September 15, 2026. StockTitan reports that BioMarin said the decision followed an assessment of study feasibility and the treatment landscape, rather than a safety or efficacy concern.

VOXZOGO setback meets growth

The program decision adds a pipeline question to an otherwise stronger operating picture. In Q2 2026, BioMarin generated USD 989.71 million in revenue, an increase of 20.00 percent from the prior-year quarter, according to StockTitan.

VOXZOGO revenue reached USD 253.00 million in the quarter. At the same time, GAAP net income declined to USD 45.00 million from USD 241.00 million in the year-earlier period, reflecting Amicus-related integration and restructuring costs, higher amortization and increased interest expense.

Quarterly beat supports guidance

BioMarin's adjusted Q2 earnings per share came to USD 1.20, versus consensus of USD 0.95, a USD 0.25 beat or 26.32 percent above expectations, according to MarketBeat. Revenue also exceeded the USD 932.03 million consensus estimate by USD 57.68 million, equivalent to 6.19 percent.

The company raised its full-year 2026 outlook to USD 3.875 billion to USD 3.925 billion in revenue and USD 4.90 to USD 5.10 in non-GAAP diluted EPS. That guidance incorporates the Amicus acquisition and gives investors a measurable test for whether the newly expanded portfolio can offset pipeline pruning.

Analysts keep targets elevated

Piper Sandler raised its BioMarin price target to USD 90.00 from USD 88.00 on September 1, 2026, while maintaining an overweight rating, MarketBeat reports. The same report places the average analyst target at USD 89.00, but also notes ratings ranging from strong buy to sell, underscoring disagreement around valuation and execution.

Market value and next report

BioMarin had a market capitalization of USD 11.6 billion as of September 30, 2026. Its 52-week range was USD 49.26 to USD 70.98, leaving the operating update and the October reporting date as the next concrete checkpoints for the stock.

MarketBeat lists BioMarin's Q3 2026 results for October 26, 2026, after the market close, with a consensus EPS estimate of USD 1.34 and expected revenue of USD 1.02 billion.